Table 5.
Efficacy data for phase 2 trials of R/M HNSCC.
| Trial Reference | Cohen et al. 2022 [15] | Ferris et al. 2018 [16] | Ruzsa et al. 2014 [17] | |||
|---|---|---|---|---|---|---|
| Agent | SD-101 | Motolimod | EMD 1201081 | |||
| Treatment Group | SD-101 8 mg + pembrolizumab | SD-101 2 mg + pembrolizumab | EXTREME regimen + motolimod | EXTREME regimen + placebo | EMD 1201081 + cetuximab | Cetuximab only |
| Number of Patients | 28 | 23 | 100 | 95 | 53 | 53 |
| Median Age | 63 | 65 | 58 | 60 | 58 | 57 |
| ORR (%) | 21 | 26 | 38 | 34 | 6 | 6 |
| CR (%) | 7 | 0 | 2 | 5 | 0 | 0 |
| PR (%) | 14 | 26 | 36 | 28 | 6 | 6 |
| SD (%) | 25 | 22 | 22 | 24 | 32 | 38 |
| PD (%) | 36 | 39 | 9 | 8 | 40 | 34 |
| Median PFS | 2.5 | 2.3 | 6.1 | 5.9 | 1.5 | 1.9 |
| Median OS | Not reached | 9 | 13.5 | 11.3 | 6.3 | - |